EVH — Evolent Health Income Statement
0.000.00%
- $1.05bn
- $1.60bn
- $2.55bn
Annual income statement for Evolent Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 925 | 908 | 1,352 | 1,964 | 2,555 |
Cost of Revenue | |||||
Gross Profit | 228 | 250 | 317 | 460 | 367 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,239 | 926 | 1,359 | 2,056 | 2,595 |
Operating Profit | -315 | -17.8 | -6.55 | -92.2 | -40.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -331 | -29.8 | -62.1 | -202 | -63 |
Provision for Income Taxes | |||||
Net Income After Taxes | -328 | -30.3 | -18.7 | -113 | -61.6 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -334 | -37.6 | -19.2 | -113 | -61.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -334 | -37.6 | -19.2 | -142 | -93.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.72 | -0.449 | 0.044 | -0.665 | -0.6 |